
Mineralys Therapeutics Reports Robust Financial Results for Q1 2024
RADNOR, PA — Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a leading biopharmaceutical company, this week announced its impressive financial results and corporate developments for the first quarter ending March 31, 2024.
Mineralys Therapeutics Reports Robust Financial Results for Q1 2024 Read More